2 Top AI Healthcare Stocks to Buy and Hold

Core Insights - The article highlights the growing impact of artificial intelligence (AI) across various industries, particularly in healthcare, with a focus on Pfizer and Eli Lilly as attractive investment opportunities due to their AI initiatives. Group 1: Pfizer - Pfizer has been utilizing AI since before the significant industry shift marked by the launch of ChatGPT in late 2022, notably in the development of its coronavirus vaccine, Comirnaty, in collaboration with BioNTech [4]. - The company is expanding its AI applications in drug discovery, commercial efforts, and manufacturing optimization to enhance efficiency and speed up the time to market for new compounds [5]. - Despite recent challenges, including declining sales from Comirnaty and upcoming patent cliffs for key products like Eliquis, Pfizer is making clinical progress with promising candidates entering phase 3 studies, such as MET-097i for weight loss and PF'4404 for cancer [6][7]. - While AI efforts may not lead to immediate business transformation, they have already contributed to significant cost reductions, and ongoing improvements in research and development could yield long-term benefits, making the stock appealing given its recent underperformance [8]. Group 2: Eli Lilly - Eli Lilly has recently constructed the most powerful supercomputer in the pharmaceutical industry with Nvidia's assistance, aimed at enhancing its capacity for novel medicine development [9]. - The company has established an AI innovation lab where its scientists collaborate with Nvidia's engineers to refine the drug discovery and development process [9]. - Eli Lilly's AI initiatives are viewed as supplementary to its already strong growth potential, positioning it as one of the top growth stocks in the healthcare sector [9].